To investigate the pathways involved in FASN protein degradation, we treated ccRCC cell lines with two classical protein degradation pathway inhibitors: MG132 (a ubiquitin-proteasome inhibitor, 10 μM), and chloroquine (an autophagy-lysosome inhibitor, 25 μM). This evidence concerns the gene FASN and nonpapillary renal cell carcinoma.